Woodford Woes Drag On For Immunocore
Unrealistic Valuations Holding Private Firms Back
Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.
You may also be interested in...
After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
Investment from Janssen helps to validate the platform developed by the San Diego-based company.